SAN FRANCISCO, CALIFORNIA | January 26, 2026 — Immusoft, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ISP-002, its investigational therapy for mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The designation recognizes the serious, life-threatening nature of the disease and underscores the potential of Immusoft’s engineered B cell platform to deliver sustained systemic enzyme replacement for pediatric patients with significant unmet medical needs.
Science Significance
The scientific importance of this milestone lies in ISP-002’s novel therapeutic modality, which leverages engineered autologous B cells as long-lived protein biofactories. MPS II is caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS), leading to progressive accumulation of glycosaminoglycans across multiple organs. ISP-002 is designed to enable continuous in vivo production of IDS following a single treatment, addressing limitations of traditional enzyme replacement therapies that require frequent lifelong infusions. By harnessing the natural persistence and bone marrow engraftment of B cells, Immusoft’s Immune System Programming (ISP™) platform represents a differentiated, next-generation approach to durable protein delivery in rare genetic disorders.
Regulatory Significance
From a regulatory perspective, FDA Rare Pediatric Disease designation is a critical validation of both the severity of MPS II and the therapeutic promise of ISP-002. The designation is reserved for treatments targeting serious or life-threatening diseases primarily affecting children, and it enables eligibility for a Priority Review Voucher (PRV) upon product approval. Such vouchers can significantly accelerate FDA review timelines for future drug or biologics applications. For cGxP professionals, the designation highlights early regulatory engagement, strengthens the IND development pathway, and signals that ISP-002 is advancing under heightened regulatory and ethical oversight appropriate for pediatric populations.
Business Significance
Advertisement
Strategically, the RPD designation enhances Immusoft’s corporate and pipeline value. Eligibility for a Priority Review Voucher—historically valued at up to hundreds of millions of dollars—represents a meaningful non-dilutive asset that can be used internally or monetized. The designation also increases investor confidence, supports future financing, and differentiates Immusoft within the competitive rare disease and cell therapy landscape. Combined with the company’s advancing ISP-001 program for MPS I, which has demonstrated favorable safety and early pharmacodynamic signals, ISP-002 strengthens Immusoft’s position as a leader in engineered B cell therapeutics.
Patients’ Significance
For patients and families affected by MPS II, the announcement is highly significant. Hunter syndrome is a progressive, multisystem disorder associated with neurocognitive decline, cardiopulmonary complications, skeletal abnormalities, and reduced life expectancy. Existing therapies place a substantial lifelong treatment burden on pediatric patients and caregivers. A therapy capable of delivering sustained enzyme levels after a single administration could dramatically reduce treatment burden while improving disease control, potentially transforming long-term outcomes and quality of life. The FDA’s recognition reinforces the urgency of advancing innovative, durable treatment options for this vulnerable population.
Policy Significance
At the policy level, the designation reflects continued FDA support for innovation in rare pediatric diseases and the use of regulatory incentives to stimulate development where commercial barriers exist. Programs such as RPD designation and PRVs are designed to align public health priorities with private-sector innovation, particularly for ultra-rare conditions with limited treatment options. As the RPD voucher program remains under legislative review, milestones like this underscore its role in enabling cutting-edge pediatric drug development while maintaining rigorous safety and compliance standards.
The FDA’s granting of Rare Pediatric Disease designation to ISP-002 marks a pivotal step in Immusoft’s mission to establish engineered B cells as a transformative therapeutic modality for rare genetic diseases. Supported by a strong scientific rationale, early clinical progress across its platform, and growing regulatory momentum, Immusoft is advancing a novel, compliance-driven approach to sustained protein delivery. For the cGxP.wire audience, this development exemplifies how regulatory incentives, advanced cell therapies, and patient-focused innovation converge to accelerate progress in rare pediatric disease treatment.
Source: Immusoft press release
